Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 6/20 | 0.59 |
| ▸ | TLR2 | O60603 | 2/20 | 0.56 |
| ▸ | MDM4 | O15151 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | TNF | P01375 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13038839 | 0.97 | MDM2 (0.58) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL25361805 | 0.96 | TLR2 (0.59) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL25361808 | 0.96 | TLR2 (0.59) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL29462653 | 0.93 | MDM2 (0.56) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL29462655 | 0.93 | MDM2 (0.56) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL30670316 | 0.93 | MDM2 (0.56) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL524544 | 0.93 | MDM2 (0.56) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL621563 | 0.93 | MDM2 (0.56) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL8892538 | 0.89 | MDM2 (0.60) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL8893047 | 0.89 | MDM2 (0.60) | MDM2TLR2MDM4TP53CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239842-A1 | BINDING MOLECULE EXHIBITING SELECTIVE BINDING FOR RAS(G12D) MUTANT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-07-18 | — | — | US | disclosed |
| WO-1996023813-A1 | PEPTIDES AND COMPOUNDS THAT BIND TO SH2 DOMAINS | AFFYMAX TECHNOLOGIES N.V. (AN) | 1996-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239842-A1 | BINDING MOLECULE EXHIBITING SELECTIVE BINDING FOR RAS(G12D) MUTANT | KRAS, G3BP1, G3BP2 | MDM2 47/4885TLR2 4719/4885MDM4 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.